These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date 2007-001493-91 A LARGE SIMPLE RANDOMIZED TRIAL OF COMBINED CHOLESTEROL MODIFICATION, BLOOD PRESSURING LOWERING IN MIDDLE AGED PEOPLE AT INTERMEDIATE (MODERATE) RISK. 2015-12-15 bad-data
Not reported 2010-024213-31 Can Vitamin D Replacement Reduce Insulin resistance In South Asians with Vitamin D Deficiency? 2014-01-08 due-trials
Not reported 2011-000284-27 A Randomised Controlled Trial for People with Established Type 2 Diabetes during Ramadan: Liraglutide versus a Sulphonylurea and/or Pioglitazone 2012-12-06 due-trials
Ongoing 2011-005545-12 Enhanced Control of Hypertension and Thrombolysis Stroke Trial not-yet-due
Ongoing 2012-002422-78 Impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes: an open lable, randomised active-comparator trial. not-yet-due
Ongoing 2014-001992-30 A randomised controlled phase II trial of oral vinorelbine as second line therapy for patients with malignant pleural mesothelioma not-yet-due
Ongoing 2014-004049-29 Investigating Aspirin and Ticagrelor for the prevention of tumour cell-induced platelet aggregation not-yet-due
Ongoing 2014-004958-34 Midazolam Measurement and Modelling using Matrix Samplers not-yet-due
Ongoing 2015-002104-91 A Randomised Controlled Trial for People with Established Type 2 Diabetes during Ramadan: Canagliflozin (Invokana™) vs. standard dual therapy regimen: The ‘Can Do Ramadan’ Study not-yet-due
Ongoing 2015-003259-24 The Effect of Sildenafil (REVATIO®) on Post Cardiac Surgery Acute Kidney Injury: A Randomised, Placebo-controlled Phase IIb Clinical Trial: The REVAKI-2 Trial not-yet-due
Ongoing 2017-002998-20 Effectiveness and cost of integrating a protocol with use of liraglutide 3.0mg into an obesity service (STRIVE Study) not-yet-due